OCGN
HealthcareOcugen, Inc. · Biotechnology · $450M
What is Ocugen, Inc.?
Ocugen is a clinical-stage biopharmaceutical company focused on developing gene therapies to cure inherited and degenerative blindness diseases. It is headquartered in Malvern, Pennsylvania.
Ocugen advances gene therapy candidates targeting retinal diseases, including inherited retinal disorders and age-related macular degeneration. The company does not yet generate product revenue and funds operations through partnerships and capital raises. Strategic alliances with CanSino Biologics and Bharat Biotech support its co-development and commercialization efforts.
Ocugen was founded in 2014 and is based in Malvern, Pennsylvania.
- OCU400 — gene therapy for inherited retinal diseases including retinitis pigmentosa
- OCU410 — gene therapy candidate for dry age-related macular degeneration
- OCU200 — fusion protein in preclinical development for diabetic eye diseases
Is OCGN a Good Stock to Buy?
UQS Score rates OCGN as Below Average overall.
The Growth, Risk, and Valuation pillars each carry a Good label, reflecting a pipeline with meaningful potential and a risk profile that is not extreme relative to clinical-stage peers.
Both the Quality and Moat pillars are rated Weak, which is typical for pre-revenue biotech companies that lack durable competitive advantages and established financial fundamentals.
See the full pillar breakdown and underlying metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does OCGN pay dividends?
No — Ocugen, Inc. does not currently pay a dividend.
Ocugen does not pay a dividend. As a clinical-stage company, capital is directed toward research, clinical trials, and pipeline development rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does OCGN report earnings?
Ocugen reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly reports focus primarily on pipeline progress, cash runway, and operating expenses rather than sales growth. Clinical milestones and partnership updates tend to drive market attention around each report.
For the most recent quarter's results, visit Ocugen's investor relations page directly.
OCGN Price History
-79.7% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Ocugen, Inc.?
Based on Ocugen, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
Frequently Asked Questions
What does Ocugen do?
Ocugen is a clinical-stage biopharmaceutical company developing gene therapies aimed at curing blindness diseases. Its pipeline targets inherited retinal diseases and age-related macular degeneration. The company has not yet commercialized a product and relies on partnerships and capital markets to fund operations.
Does OCGN pay dividends?
No, Ocugen does not pay a dividend. Clinical-stage biotechs typically reinvest all available capital into research and development. Investors seeking income should look elsewhere.
When does OCGN report earnings?
Ocugen follows a standard quarterly reporting schedule. For exact dates and the most recent filings, check the investor relations section of Ocugen's official website.
Is OCGN a good stock to buy?
UQS Score rates OCGN as Below Average overall. The Growth, Risk, and Valuation pillars are rated Good, but Quality and Moat are both Weak. This profile is common among early-stage biotech companies where pipeline potential exists but financial fundamentals are not yet established.
Is OCGN overvalued?
The Valuation pillar for OCGN carries a Good label within the UQS framework. For clinical-stage companies, valuation is often tied to pipeline probability and milestone timelines rather than traditional earnings-based metrics. The full valuation detail is available to Pro members.
What is OCGN's market cap bracket?
Ocugen is classified as a small-cap company. This places it in a segment of the market that can offer higher growth potential but also carries elevated volatility and liquidity risk compared to larger peers.
Is OCGN a long-term quality indicator?
From a long-term quality perspective, OCGN's Weak scores on Quality and Moat suggest the company has not yet built durable financial or competitive foundations. The Good Growth label indicates pipeline optionality, but long-term quality depends heavily on clinical outcomes and eventual commercialization.
What sector does OCGN belong to?
Ocugen operates in the Healthcare sector, specifically within clinical-stage biopharmaceuticals. It focuses on gene therapy, a specialized and high-risk, high-reward area of drug development targeting diseases with limited existing treatment options.
Unlock Full OCGN Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete UQS pillar breakdown across Quality, Growth, Moat, Risk, and Valuation
- ✓Access underlying financial metrics driving each pillar score
- ✓Compare OCGN side-by-side with clinical-stage peers
- ✓Track score changes as new pipeline and financial data becomes available
Pro Analysis
OCGN — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 20, 2026 | 28.4 | 2.1 | 12.0 | 65.9 | 48.1 | 29.7 | -3.1 |
| May 9, 2026 | 31.5 | 2.1 | 12.0 | 65.9 | 48.1 | 50.8 | -2.1 |
| May 8, 2026 | 33.6 | 0.0 | 12.0 | 65.9 | 36.9 | 78.9 | -2.7 |
| May 7, 2026 | 36.3 | 2.1 | 12.0 | 65.9 | 64.1 | 66.7 | +0.6 |
| May 3, 2026 | 35.7 | 2.1 | 12.0 | 65.9 | 64.1 | 62.6 | -0.2 |
| Apr 26, 2026 | 35.9 | 2.1 | 12.0 | 65.9 | 64.1 | 64.1 | +0.4 |
| Apr 19, 2026 | 35.5 | 2.1 | 12.0 | 65.9 | 64.1 | 61.0 | -0.2 |
| Apr 14, 2026 | 35.7 | 2.1 | 12.0 | 65.9 | 64.1 | 62.7 | -0.1 |
| Apr 12, 2026 | 35.8 | 2.1 | 12.0 | 65.9 | 64.1 | 63.0 | +0.1 |
| Apr 2, 2026 | 35.7 | 2.1 | 12.0 | 65.9 | 64.1 | 62.7 | — |
OCGN — Pillar Breakdown
Quality
— 2.1/100 (25%)Ocugen, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 65.9/100 (20%)Ocugen, Inc. demonstrates healthy growth trends across revenue and earnings.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Analyst consensus for future earnings growth.
Risk
— 48.1/100 (15%)Ocugen, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 29.7/100 (15%)Ocugen, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Inverse of forward P/E — higher yield means cheaper stock.
P/E relative to earnings growth — lower is more attractive.
Moat
— 12/100 (25%)Ocugen, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for OCGN.
Score Composition
Financial Data
More Stock Analysis
How is the OCGN UQS Score Calculated?
The UQS (Unified Quality Score) for Ocugen, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Ocugen, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Ocugen, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.